Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dora Dias-Santagata, Ph.D.

Co-Author

This page shows the publications co-authored by Dora Dias-Santagata and Peter Sadow.
Connection Strength

2.357
  1. Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach. Hum Pathol. 2021 08; 114:74-89.
    View in: PubMed
    Score: 0.234
  2. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol. 2020 12; 33(12):2458-2472.
    View in: PubMed
    Score: 0.222
  3. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol. 2020 11; 33(11):2186-2197.
    View in: PubMed
    Score: 0.219
  4. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020 09; 30(9):1384-1389.
    View in: PubMed
    Score: 0.219
  5. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum Pathol. 2019 01; 83:50-58.
    View in: PubMed
    Score: 0.194
  6. Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies. Thyroid. 2017 06; 27(6):819-824.
    View in: PubMed
    Score: 0.176
  7. Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr Relat Cancer. 2015 Dec; 22(6):L23-8.
    View in: PubMed
    Score: 0.160
  8. Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries (Craiova). 2015 Apr-Jun; 3(2).
    View in: PubMed
    Score: 0.153
  9. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid. 2014 Jun; 24(6):958-65.
    View in: PubMed
    Score: 0.142
  10. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90.
    View in: PubMed
    Score: 0.130
  11. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579.
    View in: PubMed
    Score: 0.117
  12. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Mar 11.
    View in: PubMed
    Score: 0.062
  13. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol. 2021 Sep; 32(3):327-335.
    View in: PubMed
    Score: 0.059
  14. BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. World J Surg. 2020 08; 44(8):2685-2691.
    View in: PubMed
    Score: 0.055
  15. Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell. 2018 08 13; 34(2):242-255.e5.
    View in: PubMed
    Score: 0.048
  16. Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells: Cytologic, Histologic, and Molecular Features. Am J Clin Pathol. 2017 Sep 01; 148(3):251-258.
    View in: PubMed
    Score: 0.045
  17. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma. Cancer Cytopathol. 2017 May; 125(5):323-331.
    View in: PubMed
    Score: 0.044
  18. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015 Dec 15; 6(40):42445-67.
    View in: PubMed
    Score: 0.040
  19. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014 Nov; 99(11):E2457-62.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.